Medicx­i's David Grainger and Francesco De Ru­ber­tis pump €200M in­to six com­pa­nies and what they say is a first-of-its kind fund

In what they’re billing as a first for biotech, David Grainger, Francesco De Ru­ber­tis and their team at Medicxi have put down €200 mil­lion to sweep up stakes in six com­pa­nies from their pre­de­ces­sor VC and pump new mon­ey in­to them.

Medicxi didn’t dis­close which com­pa­nies it was in­vest­ing in but the port­fo­lio draws from In­dex Ven­tures Life VI, one of the last funds the Medicxi team launched while they were still part of the multi­na­tion­al, tech-fo­cused VC firm In­dex Ven­tures. That team kept ad­vis­ing In­dex on their life sci­ences port­fo­lio even af­ter they spun out to form their own firm in the mid­dle of 2016.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER